RTTNews BiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 22:01:24时区推断·⟳ 抓取 22:15:36·⚡ 决策 07-17 22:23:01 +7m25s·102.0 天前
REGENXBIO定价1亿美元公开发行后股价大跌
1亿美元公开发行价格9美元带来明确摊薄压力，方向偏利空。
📄 原文RTTNews Biotech↗ 原文
REGENXBIO Prices $100M Public Offering To Advance Gene Therapy Programs; Stock Down
Shares of REGENXBIO Inc. (RGNX) fell nearly 20% after the company announced it has priced a $100 million public offerin…
不做 REGENXBIO（RGNX.US）
利空已在7月13日披露并大幅反应，当前摄取已滞后；不以已跌20%的发行摊薄消息追空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-13 · 扩散 medium · price-in 风险 high ↗
关键理由
- 1亿美元公开发行价格9美元带来明确摊薄压力，方向偏利空。
主要风险
- 消息称股价已下跌约20%并接近发行价，继续追空的风险收益不佳。
原文全文
展开原文 · 1,290 字
Shares of REGENXBIO Inc. (RGNX) fell nearly 20% after the company announced it has priced a $100 million public offering of common stock and pre-funded warrants.
The offering includes 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, before underwriting discounts and commissions. Gross proceeds are expected to total about $100 million, with closing scheduled for July 20, 2026, subject to customary closing conditions.
REGENXBIO has also granted underwriters a 30-day option to purchase up to 1,667,250 additional shares at the public offering price. Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers.
RGNX has traded between $5.45 and $16.19 over the past year. The stock is currently trading at $8.96, down 20.00%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 13, 2026 10:12 ET The week saw the release of the minutes of the Federal Reserve’s latest monetary policy session, foreign trade figures and survey data on manufacturing and services in the U.S. External trade data from Germany was the highlight in Europe, while the latest macroeconomic projections from the Asian Development Bank and the International Monetary Fund gained attention.
The offering includes 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, before underwriting discounts and commissions. Gross proceeds are expected to total about $100 million, with closing scheduled for July 20, 2026, subject to customary closing conditions.
REGENXBIO has also granted underwriters a 30-day option to purchase up to 1,667,250 additional shares at the public offering price. Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers.
RGNX has traded between $5.45 and $16.19 over the past year. The stock is currently trading at $8.96, down 20.00%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 13, 2026 10:12 ET The week saw the release of the minutes of the Federal Reserve’s latest monetary policy session, foreign trade figures and survey data on manufacturing and services in the U.S. External trade data from Germany was the highlight in Europe, while the latest macroeconomic projections from the Asian Development Bank and the International Monetary Fund gained attention.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。